Healthcare professionals Careers Media About us Contact us Search Search Home What we do Our medicines Community Partnerships Inside ViiV Healthcare Media Press releases These press releases are intended for business journalists and analysts/investors. Filter by year Show all 2015 2014 2013 2012 2011 2010 2009 Search by keyword 2 Jul 2015 ViiV Healthcare and Desano Pharmaceuticals’ manufacturing agreement will allow competitive supply of dolutegravir in China and several developing countries ViiV Healthcare and Desano Pharmaceuticals’ manufacturing agreement will allow competitive supply of dolutegravir in China and several developing countries 22 Jun 2015 ViiV Healthcare Announces New Positive Action Project in U.S. for MSM Youth, Calls for Proposals ViiV Healthcare Announces New Positive Action Project in U.S. for MSM Youth, Calls for Proposals 26 May 2015 Press Release ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV 13 May 2015 European Patient Advocacy Groups Awarded Grants from Positive Action Europe European Patient Advocacy Groups Awarded Grants from Positive Action Europe 6 May 2015 ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy 31 Mar 2015 ViiV Healthcare Launches New Global Positive Action Programme Focused on MSM and Transgender Populations ViiV Healthcare Launches New Global Positive Action Programme Focused on MSM and Transgender Populations 16 Mar 2015 ViiV Healthcare announces the approval in Japan of Triumeq® (dolutegravir, abacavir and lamivudine), a new single-pill regimen for the treatment of HIV infection ViiV Healthcare announces the approval in Japan of Triumeq® (dolutegravir, abacavir and lamivudine), a new single-pill regimen for the treatment of HIV infection. 4 Feb 2015 ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men 15 Dec 2014 ViiV Healthcare announces regulatory submission in Japan for single-pill regimen combining dolutegravir, abacavir and lamivudine for the treatment of HIV ViiV Healthcare has today, 15 December 2014, submitted a regulatory application to the Ministry of Health, Labour and Welfare (MHLW) in Japan for the single-pill regimen combining dolutegravir, abacavir and lamivudine for the treatment of HIV infection. 4 Dec 2014 Mylan's tentative FDA approval for paeds formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and CHAI Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative 27 Nov 2014 ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV 21 Nov 2014 HIV Testing Week ViiV Healthcare is proud to support the second European HIV testing week 18 Nov 2014 GSK ranked top of the 2014 Access to Medicines (ATM) Index for the fourth consecutive time. GSK ranked top of the 2014 Access to Medicines (ATM) Index for the fourth consecutive time. 20 Oct 2014 ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S. Positive Action Southern Initiative Commitment Continues with New Grants Awarded to Seven Organizations, Bringing Total Funding for Grassroots Projects to More than 2.8 Million to Date. 22 Aug 2014 ViiV Healthcare receives FDA approval for Triumeq ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection. Previous 1 2 3 4 5 Next Media contacts For our corporate press office, email: Sébastien Desprez OR call +44 7920 567 707 For US-specific media enquiries, email: marc.s.meachem@viivhealthcare.com OR call +1 919 483 8756 ©2015 ViiV Healthcare. Accessibility Privacy policy Terms of use Terms and conditions Connect with us